Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics

Brand Names


Austria: Eldisin; Belgium: Eldisine; Finland: Eldisine; France: Eldisine; Germany: Eldisine, Gesidine; Greece: Eldesine, Gesidine; Italy: Eldisine; Luxembourg: Eldisine; Portugal: Gesidine; Spain: Enisón; Sweden: Eldisine.


Japan: Fildesin.

Drug combinations


Vindesine: C~43~H~55~N~5~O~7~. Mw: 753.93. (1) Vincaleukoblastine, 23-amino-O^4^-deacetyl-23-demethoxy-; (2) 3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine. CAS-53643-48-4 (1976).

Pharmacologic Category

Antineoplastic Agents, Vinca Alkaloid. Natural Source (Plant) Derivative. (ATC-Code: L01CA03).

Mechanism of action

Vindesine arrests cell division in metaphase through inhibition of microtubular formation of mitotic spindle.

Therapeutic use

Investigational: Management of acute lymphocytic leukemia, chronic myelogenous leukemia. Breast, head, neck, and lung cancers. Lymphomas (Hodgkin’s and non-Hodgkin).

Pregnancy and lactiation implications

Unlabeled use


Hypersensitivity to vindesine, vinca alkaloids, or any component of the formulation.

Warnings and precautions

Hazardous agent. Use with caution (if at all) in hepatic impairment, or in neurologic problems. Vindesine reported to display cross-resistance with vincristine. Not for intrathecal administration (may be fatal).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart